Effect of Probenecid on Synovial Fluid ATP Levels in CPPD

Summary

This study will investigate the hypothesis that probenecid, a medication currently used for gout, reduces levels of ATP in the joint fluid of patients with calcium pyrophosphate deposition disease (CPPD), another common type of crystal-related arthritis. There is good evidence that CPPD results from an excess of ATP in joints. The investigators will measure levels of ATP in joint fluid before and after 5 days of treatment with probenecid. This study will serve to rationalize larger studies of probenecid in CPPD.

Timeline

Start

2014-10-15

Primary completion

2021-04-08

Completion

2021-04-08

Drugs

Indications